More on Alexion Pharmaceuticals' (ALXN) Q3 report: Steers revenue guidance higher, now seeing...

|About: Alexion Pharmaceuticals, ... (ALXN)|By:, SA News Editor

More on Alexion Pharmaceuticals' (ALXN) Q3 report: Steers revenue guidance higher, now seeing $770M-$775M from the previously announced range of $760M-$768M. Lowers the expectation for its GAAP tax rate for FY11 to a range of 20%-22%, from 30%-32%. Shares +1% premarket. (PR)